Skip to main content
. 2020 Apr 30;2020:7935475. doi: 10.1155/2020/7935475

Figure 2.

Figure 2

Progression-free survival. Intent-to-treat analysis demonstrated a median PFS of 19.4 months in the treatment group and 8.6 months in the control group.